Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Heron Therapeutics files to sell 12.44M shares of common stock for holders  16:20
05/28/21
05/28
16:20
05/28/21
16:20
HRTX

Heron Therapeutics

$13.26 /

-0.235 (-1.74%)

 
ShowHide Related Items >><<
HRTX Heron Therapeutics
$13.26 /

-0.235 (-1.74%)

HRTX Heron Therapeutics
$13.26 /

-0.235 (-1.74%)

05/10/21 Cantor Fitzgerald
Cantor Fitzgerald remains bullish on Heron amid HTX-011 labeling discussions
01/21/21 SVB Leerink
Pacira downgraded to Market Perform from Outperform at SVB Leerink
09/08/20 Cowen
Heron Therapeutics' HTX-011 submission to be Class 2, says Cowen
08/14/20 SVB Leerink
SVB Leerink sees $4 per share upside if Heron proposal accepted by FDA
HRTX Heron Therapeutics
$13.26 /

-0.235 (-1.74%)

Syndicate
Heron Therapeutics offers to sell $150M in convertible debt due 2026 » 09:15
05/25/21
05/25
09:15
05/25/21
09:15
HRTX

Heron Therapeutics

$13.49 /

-0.23 (-1.68%)

J. Wood Capital Advisors…

J. Wood Capital Advisors LLC acted as financial advisor and Gibson, Dunn & Crutcher LLP acted as legal advisor to Heron on the transaction.

ShowHide Related Items >><<
HRTX Heron Therapeutics
$13.49 /

-0.23 (-1.68%)

HRTX Heron Therapeutics
$13.49 /

-0.23 (-1.68%)

05/10/21 Cantor Fitzgerald
Cantor Fitzgerald remains bullish on Heron amid HTX-011 labeling discussions
01/21/21 SVB Leerink
Pacira downgraded to Market Perform from Outperform at SVB Leerink
09/08/20 Cowen
Heron Therapeutics' HTX-011 submission to be Class 2, says Cowen
08/14/20 SVB Leerink
SVB Leerink sees $4 per share upside if Heron proposal accepted by FDA
HRTX Heron Therapeutics
$13.49 /

-0.23 (-1.68%)

Over a month ago
Hot Stocks
Landec subsidiary announces Heron received FDA approval for ZYNRELEF » 08:27
05/17/21
05/17
08:27
05/17/21
08:27
LNDC

Landec

$12.15 /

+0.39 (+3.32%)

, HRTX

Heron Therapeutics

$13.84 /

-1.695 (-10.91%)

Lifecore Biomedical, a…

Lifecore Biomedical, a fully-owned subsidiary of Landec (LNDC), announced the receipt by Heron Therapeutics (HRTX), one of Lifecore's customers, of FDA approval for its ZYNRELEF candidate on May 13 for which for Lifecore provides CDMO support. Heron received FDA approval for ZYNRELEF extended-release solution for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty.

ShowHide Related Items >><<
LNDC Landec
$12.15 /

+0.39 (+3.32%)

HRTX Heron Therapeutics
$13.84 /

-1.695 (-10.91%)

LNDC Landec
$12.15 /

+0.39 (+3.32%)

04/08/21 Lake Street
Landec price target lowered to $12 from $13 at Lake Street
06/30/20
Fly Intel: Top five analyst downgrades
06/30/20 Lake Street
Landec price target raised to $11 after revenue beat at Lake Street
06/30/20 Barrington
Landec downgraded to Market Perform from Outperform at Barrington
HRTX Heron Therapeutics
$13.84 /

-1.695 (-10.91%)

05/10/21 Cantor Fitzgerald
Cantor Fitzgerald remains bullish on Heron amid HTX-011 labeling discussions
01/21/21 SVB Leerink
Pacira downgraded to Market Perform from Outperform at SVB Leerink
09/08/20 Cowen
Heron Therapeutics' HTX-011 submission to be Class 2, says Cowen
08/14/20 SVB Leerink
SVB Leerink sees $4 per share upside if Heron proposal accepted by FDA
LNDC Landec
$12.15 /

+0.39 (+3.32%)

HRTX Heron Therapeutics
$13.84 /

-1.695 (-10.91%)

LNDC Landec
$12.15 /

+0.39 (+3.32%)

LNDC Landec
$12.15 /

+0.39 (+3.32%)

Hot Stocks
Heron Therapeutics announces U.S. FDA approval of ZYNRELEF » 08:04
05/13/21
05/13
08:04
05/13/21
08:04
HRTX

Heron Therapeutics

$17.39 /

-1.095 (-5.93%)

Heron Therapeutics…

Heron Therapeutics announced that the U.S. FDA has approved ZYNRELEF extended-release solution for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty. ZYNRELEF, the first and only extended-release dual-acting local anesthetic, delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. The synergy between bupivacaine and meloxicam in ZYNRELEF has resulted in patients experiencing significantly less pain, including severe pain, and significantly more patients requiring no opioids after surgery as compared to bupivacaine solution, the current standard-of-care.

ShowHide Related Items >><<
HRTX Heron Therapeutics
$17.39 /

-1.095 (-5.93%)

HRTX Heron Therapeutics
$17.39 /

-1.095 (-5.93%)

05/10/21 Cantor Fitzgerald
Cantor Fitzgerald remains bullish on Heron amid HTX-011 labeling discussions
01/21/21 SVB Leerink
Pacira downgraded to Market Perform from Outperform at SVB Leerink
09/08/20 Cowen
Heron Therapeutics' HTX-011 submission to be Class 2, says Cowen
08/14/20 SVB Leerink
SVB Leerink sees $4 per share upside if Heron proposal accepted by FDA
HRTX Heron Therapeutics
$17.39 /

-1.095 (-5.93%)

Recommendations
Cantor Fitzgerald remains bullish on Heron amid HTX-011 labeling discussions » 10:27
05/10/21
05/10
10:27
05/10/21
10:27
HRTX

Heron Therapeutics

$18.34 /

+1.68 (+10.08%)

Post Q1, Cantor…

Post Q1, Cantor Fitzgerald analyst Brandon Folkes reiterates an Overweight rating and a price target of $26 on Heron Therapeutics' shares. The analyst continues to believe the stock offers investors a favorable risk/reward at current levels. Further, he remains bullish on the peak sales potential for HTX-011 and expects an approval of HTX-011 in 2021. With renewed growth in the CINV franchise and a growing pipeline of products, Folkes believes the company will drive value for investors through not only the launch of HTX-011, but also through the rest of the business. The analyst also highlights that the company noted the are no outstanding questions with the FDA for HTX-011, and is currently in labeling discussions with the FDA.

ShowHide Related Items >><<
HRTX Heron Therapeutics
$18.34 /

+1.68 (+10.08%)

HRTX Heron Therapeutics
$18.34 /

+1.68 (+10.08%)

01/21/21 SVB Leerink
Pacira downgraded to Market Perform from Outperform at SVB Leerink
09/08/20 Cowen
Heron Therapeutics' HTX-011 submission to be Class 2, says Cowen
08/14/20 SVB Leerink
SVB Leerink sees $4 per share upside if Heron proposal accepted by FDA
07/06/20 Needham
Pacira price target raised to $64 from $52 at Needham
HRTX Heron Therapeutics
$18.34 /

+1.68 (+10.08%)

Earnings
Heron Therapeutics reports Q1 EPS (58c), consensus (57c) » 08:37
05/10/21
05/10
08:37
05/10/21
08:37
HRTX

Heron Therapeutics

$16.66 /

+0.02 (+0.12%)

Reports Q1 revenue $20M,…

Reports Q1 revenue $20M, consensus $25.73M. "We have no outstanding questions on the pending NDA and are currently in labelling discussions with the FDA, as we prepare for the anticipated commercial launch of HTX-011 in the U.S.," said CEO Barry Quart. "For the oncology care franchise, we expect the market to pick up in the second quarter and we recently signed a large, multi-year contract for CINVANTI that will help increase net product sales throughout 2021."

ShowHide Related Items >><<
HRTX Heron Therapeutics
$16.66 /

+0.02 (+0.12%)

HRTX Heron Therapeutics
$16.66 /

+0.02 (+0.12%)

01/21/21 SVB Leerink
Pacira downgraded to Market Perform from Outperform at SVB Leerink
09/08/20 Cowen
Heron Therapeutics' HTX-011 submission to be Class 2, says Cowen
08/14/20 SVB Leerink
SVB Leerink sees $4 per share upside if Heron proposal accepted by FDA
07/06/20 Needham
Pacira price target raised to $64 from $52 at Needham
HRTX Heron Therapeutics
$16.66 /

+0.02 (+0.12%)

Over a quarter ago
Earnings
Heron Therapeutics reports Q4 EPS (68c), consensus (65c) » 08:41
02/24/21
02/24
08:41
02/24/21
08:41
HRTX

Heron Therapeutics

$17.83 /

-0.575 (-3.12%)

Reports Q4 revenue…

Reports Q4 revenue $20.6M, consensus $19.14M. As of December 31, 2020, Heron had cash, cash equivalents and short-term investments of $208.5M vs. $391.0M as of December 31, 2019. "We are very pleased that we exceeded our CINV sales guidance for the year, despite 2020 being a challenging year for Heron, with our CINV franchise impacted by both the COVID-19 global pandemic and the EMEND(R) IV generic arbitrage. We also achieved several important milestones in 2020, including the authorization of ZYNRELEF in Europe and the advancement of HTX-034 for postoperative pain and HTX-019 for PONV into clinical development," said Barry Quart, Pharm.D., Chairman and Chief Executive Officer of Heron. "We believe that 2021 will be a transformational year for Heron, with significant growth expected in our CINV products with net product sales guidance of $130 million to $145 million, the anticipated FDA approval and commercial launch of HTX-011 in the U.S., and the submission of an NDA for HTX-019 for PONV in the fourth quarter."

ShowHide Related Items >><<
HRTX Heron Therapeutics
$17.83 /

-0.575 (-3.12%)

HRTX Heron Therapeutics
$17.83 /

-0.575 (-3.12%)

01/21/21 SVB Leerink
Pacira downgraded to Market Perform from Outperform at SVB Leerink
09/08/20 Cowen
Heron Therapeutics' HTX-011 submission to be Class 2, says Cowen
08/14/20 SVB Leerink
SVB Leerink sees $4 per share upside if Heron proposal accepted by FDA
07/06/20 Needham
Pacira price target raised to $64 from $52 at Needham
HRTX Heron Therapeutics
$17.83 /

-0.575 (-3.12%)

Downgrade
Pacira downgraded to Market Perform from Outperform at SVB Leerink » 08:44
01/21/21
01/21
08:44
01/21/21
08:44
PCRX

Pacira

$73.41 /

-0.4 (-0.54%)

, HRTX

Heron Therapeutics

$17.60 /

-0.35 (-1.95%)

SVB Leerink analyst Ami…

SVB Leerink analyst Ami Fadia downgraded Pacira (PCRX) to Market Perform from Outperform with a price target of $75, up from $63, following results from her latest MEDACorp physician post-op pain survey. The analyst believes HTX-011 will finally get approval by the May 12 PDUFA date and impact Exparel's growth going forward. Her latest MEDACorp physician post-op pain survey reaffirms prior key opinion leaders' feedback that Exparel growth will be adversely impacted by HTX-011 due to better perceived duration of pain relief, opioid reduction properties, and a lower price point for HTX-011 versus Exparel based on Heron (HRTX) management's commentary. While Exparel has demonstrated good resiliency in the COVID environment, Fadia doesn't believe this means Exparel has an improved competitive moat versus HTX-011 based on physician feedback, and at the current stock price of $73/share, she believes the risk/reward is more balanced at current levels.

ShowHide Related Items >><<
PCRX Pacira
$73.41 /

-0.4 (-0.54%)

HRTX Heron Therapeutics
$17.60 /

-0.35 (-1.95%)

PCRX Pacira
$73.41 /

-0.4 (-0.54%)

01/20/21 Piper Sandler
Pacira price target raised to $90 from $65 at Piper Sandler
01/06/21 RBC Capital
Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas
12/14/20 Barclays
Pacira price target raised to $79 from $73 at Barclays
09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
HRTX Heron Therapeutics
$17.60 /

-0.35 (-1.95%)

09/08/20 Cowen
Heron Therapeutics' HTX-011 submission to be Class 2, says Cowen
08/14/20 SVB Leerink
SVB Leerink sees $4 per share upside if Heron proposal accepted by FDA
07/06/20 Needham
Pacira price target raised to $64 from $52 at Needham
07/01/20 RBC Capital
Pacira price target raised to $62 from $56 at RBC Capital
PCRX Pacira
$73.41 /

-0.4 (-0.54%)

HRTX Heron Therapeutics
$17.60 /

-0.35 (-1.95%)

Hot Stocks
Heron Therapeutics' HTX-011 featured in published study » 08:36
01/21/21
01/21
08:36
01/21/21
08:36
HRTX

Heron Therapeutics

$17.60 /

-0.35 (-1.95%)

Heron Therapeutics…

Heron Therapeutics announced that the results from an EPOCH 1 follow-on study of the investigational agent HTX-011 in bunionectomy, have been published online, by the Journal of the American Podiatric Medical Association. In this study, 77% of patients receiving HTX-011, along with postoperative over-the-counter oral acetaminophen and ibuprofen, remained opioid-free through the 72-hour period following surgery and continued to be opioid-free through 28 days of recovery. The mean pain intensity never rose above the mild range through 72 hours postoperatively. HTX-011 is a fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-011 was well tolerated, with a safety profile comparable to placebo and bupivacaine solution. Heron resubmitted an NDA to the FDA for HTX-011 in November 2020 and the FDA set a Prescription Drug User Fee Act goal date of May 12, 2021. Heron is working to respond to a list of questions received from Health Canada in July 2020.

ShowHide Related Items >><<
HRTX Heron Therapeutics
$17.60 /

-0.35 (-1.95%)

HRTX Heron Therapeutics
$17.60 /

-0.35 (-1.95%)

09/08/20 Cowen
Heron Therapeutics' HTX-011 submission to be Class 2, says Cowen
08/14/20 SVB Leerink
SVB Leerink sees $4 per share upside if Heron proposal accepted by FDA
07/06/20 Needham
Pacira price target raised to $64 from $52 at Needham
07/01/20 RBC Capital
Pacira price target raised to $62 from $56 at RBC Capital
HRTX Heron Therapeutics
$17.60 /

-0.35 (-1.95%)

Hot Stocks
Heron Therapeutics says NDA resubmission for HTX-011 under review » 08:42
01/11/21
01/11
08:42
01/11/21
08:42
HRTX

Heron Therapeutics

$19.58 /

+0.05 (+0.26%)

The New Drug Application…

The New Drug Application resubmission for HTX-011, an investigational agent for the management of postoperative pain, submitted November 12, 2020 to the U.S. FDA, continues under review. The FDA set a Prescription Drug User Fee Act goal date of May 12, 2021. In the Phase 1b portion of this Phase 1b/2 double-blind, randomized, active-controlled dose-escalation study in 33 patients undergoing bunionectomy, the reduction in pain intensity observed with the lowest dose of HTX-034 evaluated (containing 21.7 mg of bupivacaine plus meloxicam and aprepitant) was greater than the bupivacaine 50 mg solution group through 96 hours. In addition, 45.5% of HTX-034 patients remained opioid-free through Day 15 with median opioid consumption of 2.5 milligram morphine equivalents (same as one 5 mg oxycodone pill) through 72-hours, a 71% reduction compared to bupivacaine solution. The expanded Phase 2 portion of the study for HTX-034 will begin this quarter.

ShowHide Related Items >><<
HRTX Heron Therapeutics
$19.58 /

+0.05 (+0.26%)

HRTX Heron Therapeutics
$19.58 /

+0.05 (+0.26%)

09/08/20 Cowen
Heron Therapeutics' HTX-011 submission to be Class 2, says Cowen
08/14/20 SVB Leerink
SVB Leerink sees $4 per share upside if Heron proposal accepted by FDA
07/06/20 Needham
Pacira price target raised to $64 from $52 at Needham
07/01/20 RBC Capital
Pacira price target raised to $62 from $56 at RBC Capital
HRTX Heron Therapeutics
$19.58 /

+0.05 (+0.26%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.